Search

Your search keyword '"Simon, Mallal"' showing total 269 results

Search Constraints

Start Over You searched for: Author "Simon, Mallal" Remove constraint Author: "Simon, Mallal" Language undetermined Remove constraint Language: undetermined
269 results on '"Simon, Mallal"'

Search Results

1. Idiopathic subglottic stenosis arises at the epithelial interface of host and pathogen

2. Immunodominant MHC-II (Major Histocompatibility Complex II) Restricted Epitopes in Human Apolipoprotein B

3. Supplementary fig 1 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

4. Supplementary fig 10 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

5. Supplementary Dataset 2 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

6. Supplementary fig 5 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

7. Supplementary fig 16 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

8. Supplementary fig 12 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

9. Supplementary Dataset 1 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

10. Supplementary fig 2 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

11. Data from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

12. Supplementary fig 11 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

13. Supplementary fig 7 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

14. Supplementary fig 3 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

15. Supplementary fig 6 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

16. Supplementary Data from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

17. Supplementary fig 4 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

18. Supplementary fig 14 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

19. Supplementary fig 13 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

20. Supplementary fig 17 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

21. Supplementary fig 15 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

22. Supplementary fig 8 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

23. Circulating CD4+ TEMRA and CD4+ CD28− T cells and incident diabetes among persons with and without HIV

24. Targets and cross-reactivity of human T cell recognition of Common Cold Coronaviruses

25. Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level

26. HLA-II-Associated HIV-1 Adaptation Decreases CD4 + T-Cell Responses in HIV-1 Vaccine Recipients

27. Anticytomegalovirus CD4 + T Cells Are Associated With Subclinical Atherosclerosis in Persons With HIV

28. Adaptation to HLA-associated immune pressure over the course of HIV infection and in circulating HIV-1 strains

29. Positive Selection of Mutations in the Helicobacter pylori katA 5′ Untranslated Region in a Mongolian Gerbil Model of Gastric Disease

30. Deep Sequencing Analysis of Individual HIV-1 Proviruses Reveals Frequent Asymmetric Long Terminal Repeats

31. Positive Selection of Mutations in the Helicobacter pylori

32. Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

33. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

34. The Proximal Airway Is a Reservoir for Adaptive Immunologic Memory in Idiopathic Subglottic Stenosis

35. New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals

36. Abstract P3-08-15: Immunologic correlates of long-term outcome in the residual disease of triple-negative breast cancer after neoadjuvant chemotherapy

37. White Adipose Tissue Compositional and Transcriptional Patterns with Progressive Glucose Intolerance in Persons with HIV

38. Idiopathic subglottic stenosis arises at the interface of host and pathogen

39. Cytotoxic T cells specific for alpha-myosin drive immunotherapy related myocarditis

40. SARS-CoV-2 vaccination induces immunological memory able to cross-recognize variants from Alpha to Omicron

41. Cross-Reactivity to Mutated Viral Immune Targets Can Influence CD8+ T Cell Functionality: An Alternative Viral Adaptation Strategy

42. Altered subgenomic RNA abundance provides unique insight into SARS-CoV-2 B.1.1.7/Alpha variant infections

43. Immunological Interaction of HLA-DPB1 and Proteinase 3 in ANCA Vasculitis is Associated with Clinical Disease Activity

44. CD4+CCR6+ T cells dominate the BCG-induced transcriptional signature

45. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

46. Widespread Tau-Specific CD4 T Cell Reactivity in the General Population

47. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms

48. Clinical and evolutionary consequences of HIV adaptation to HLA

49. Dengue-specific CD8+ T cell subsets display specialized transcriptomic and TCR profiles

50. Cross-Reactivity to Mutated Viral Immune Targets Can Influence CD8

Catalog

Books, media, physical & digital resources